David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I think SRRK stock could be a Buy.

Scholar Rock Holding Corp.’s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.

The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.

Scholar Rock announced that Dr. Srinivas Akkaraju has been appointed to Scholar Rock’s Board of Directors as an independent director.

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.

Scholar Rock contends its experimental drug for spinal muscular atrophy can achieve what none of the currently available therapies can do to treat this rare disease. After positive data from a ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks ...

Scholar Rock's surprising success Apitegromab is an antibody that binds to another protein called myostatin, which normally works to limit muscle growth. It's being tested in the phase 3 Sapphire ...

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in ...